The efficacy and tolerability of frovatriptan and dexketoprofen for the treatment of acute migraine attacks

References

• Lipton RB. Chronic migraine, classification, differential diagnosis, and epidemiology. Headache 2011;51(Suppl 2):77-83
   PubMedGoogle Scholar
• Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;55(6):754-62
   PubMed Web of Science ®Google Scholar
• Steiner TJ, Paemeleire K, Jensen R, et al. European Headache Federation; Lifting The Burden: the Global Campaign to Reduce the Burden of Headache Worldwide; World Health Organization. European principles of management of common headache disorders in primary care. J Headache Pain 2007;8(Suppl 1):S3-47
   PubMed Web of Science ®Google Scholar
• Evers S, Afra J, Frese A, et al. European Federation of Neurological Societies. EFNS guideline on the drug treatment of migraine-revised report of an EFNS task force. Eur J Neurol 2009;16(9):968-81
   PubMed Web of Science ®Google Scholar
• Sarchielli P, Granella F, Prudenzano MP, et al. Italian guidelines for primary headaches: 2012 revised version. J Headache Pain 2012;13(Suppl 2):S31-70
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Holland S, Freitag F, et al. Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012;78(17):1337-45
   PubMed Web of Science ®Google Scholar
• Worthington I, Pringsheim T, Gawel MJ, et al. Canadian Headache Society Acute Migraine Treatment Guideline Development Group. Canadian Headache Society Guideline: acute drug therapy for migraine headache. Can J Neurol Sci 2013;40(5 Suppl 3):S1-80
   PubMed Web of Science ®Google Scholar
• Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002;22(8):633-58
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Lipton RB, Ferrari MD. Migraine-current understanding and treatment. N Engl J Med 2002;346(4):257-70
   PubMed Web of Science ®Google Scholar
• Fox AW. Comparative tolerability of oral 5-HT1B/1D agonists. Headache 2000;40(7):521-7
   PubMedGoogle Scholar
• Ng-Mak DS, Hu XH, Chen YT, Ma L. Acute migraine treatment with oral triptans and NSAIDs in a managed care population. Headache 2008;48(8):1176-85
   PubMedGoogle Scholar
• Blumenfeld A, Gennings C, Cady R. Pharmacological synergy: the next frontier on therapeutic advancement for migraine. Headache 2012;52(4):636-47
   PubMedGoogle Scholar
• Loder E. Fixed drug combinations for the acute treatment of migraine: place in therapy. CNS Drugs 2005;19(9):769-84
   PubMedGoogle Scholar
• Lipton RB, Serrano D, Nicholson RA, et al. Impact of NSAID and Triptan Use on Developing Chronic Migraine: results From the American Migraine Prevalence and Prevention (AMPP) Study. Headache 2013;53(10):1548-63
   PubMedGoogle Scholar
• Cleves C, Tepper SJ. Sumatriptan/naproxen sodium combination for the treatment of migraine. Expert Rev Neurother 2008;8(9):1289-97
   PubMedGoogle Scholar
• Samsam M. Central nervous system acting drugs in treatment of migraine headache. Cent Nerv Syst Agents Med Chem 2012;12(3):158-72
   PubMedGoogle Scholar
• Jhee SS, Shiovitz T, Crawford AW, Cutler NR. Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review. Clin Pharmacokinet 2001;40(3):189-205
   PubMedGoogle Scholar
• Barbanoj MJ, Antonijoan RM, Gich I. Clinical pharmacokinetics of dexketoprofen. Clin Pharmacokinet 2001;40(4):245-62
   PubMed Web of Science ®Google Scholar
• Negro A, Lionetto L, Casolla B, et al. Pharmacokinetic evaluation of frovatriptan. Expert Opin Drug Metab Toxicol 2011;7(11):1449-58
   PubMed Web of Science ®Google Scholar
• Sanford M. Frovatriptan: a review of its use in the acute treatment of migraine. CNS Drugs 2012;26(9):791-811
   PubMed Web of Science ®Google Scholar
• Cortelli P, Allais G, Tullo V, et al. Frovatriptan versus other triptans in the acute treatment of migraine: pooled analysis of three double-blind, randomized, cross-over, multicenter, Italian studies. Neurol Sci 2011;32(Suppl(1):S95-8
   PubMedGoogle Scholar
• Allais G, Benedetto C. A review of the use of frovatriptan in the treatment of menstrually related migraine. Ther Adv Neurol Disord 2013;6(2):55-67
   PubMed Web of Science ®Google Scholar
• Hu Y, Guan X, Fan L, Jin L. Triptans in prevention of menstrual migraine: a systematic review with meta-analysis. J Headache Pain 2013;14(1):7
   PubMedGoogle Scholar
• Adelman JU, Belsey J. Meta-analysis of oral triptan therapy for migraine: number needed to treat and relative cost to achieve relief within 2 hours. J Manag Care Pharm 2003;9(1):45-52
   PubMedGoogle Scholar
• Poolsup N, Leelasangaluk V, Jittangtrong J, et al. Efficacy and tolerability of frovatriptan in acute migraine treatment: systematic review of randomized controlled trials. J Clin Pharm Ther 2005;30(6):521-32
   PubMedGoogle Scholar
• Barbanoj MJ, Antonijoan RM, Gich I. Clinical pharmacokinetics of dexketoprofen. Clin Pharmacokinet 2001;40(4):245-62
   PubMed Web of Science ®Google Scholar
• Allais G, De Lorenzo C, Airola G, et al. Dexketoprofen trometamol in the treatment of acute migraine attack. Minerva Med 2000;91(7-8):153-9
   PubMedGoogle Scholar
• Mainardi F, Maggioni F, Pezzola D, et al. Dexketoprofen trometamol in the acute treatment of migraine attack: a phase II, randomized, double-blind, crossover, placebo-controlled, dose optimization study. J Pain 2014;15(4):388-94
   PubMedGoogle Scholar
• Tullo V, Valguarnera F, Barbanti P, et al. Comparison of frovatriptan plus dexketoprofen (25 mg or 37.5 mg) with frovatriptan alone in the treatment of migraine attacks with or without aura: a randomized study. Cephalalgia 2014;34(6):434-45
   PubMedGoogle Scholar
• Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004;24(Suppl 1):9-160
   PubMed Web of Science ®Google Scholar
• Bartolini M, Giamberardino MA, Lisotto C, et al. A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine. J Headache Pain 2011;12(3):361-8
   PubMed Web of Science ®Google Scholar
• Savi L, Omboni S, Lisotto C, et al. A double-blind, randomized, multicenter, Italian study of frovatriptan versus rizatriptan for the acute treatment of migraine. J Headache Pain 2011;12(2):219-26
   PubMedGoogle Scholar
• Tullo V, Allais G, Ferrari MD, et al. Frovatriptan versus zolmitriptan for the acute treatment of migraine: a double-blind, randomized, multicenter, Italian study. Neurol Sci 2010;31(Suppl 1):S51-4
   PubMedGoogle Scholar
• Derosier FJ, Lewis D, Hershey AD, et al. Randomized trial of sumatriptan and naproxen sodium combination in adolescent migraine. Pediatrics 2012;129(6):e1411-20
   PubMed Web of Science ®Google Scholar
• Loder E, Weizenbaum E. Adding NSAIDs to triptans: could less be more? Cephalalgia 2014;34(6):407-8
   PubMedGoogle Scholar
• Martin VT, Lipton RB. Epidemiology and biology of menstrual migraine. Headache 2008;48(Suppl 3):S124-30
   PubMedGoogle Scholar
• Granella F, Sances G, Allais G, et al. Characteristics of menstrual and nonmenstrual attacks in women with menstrually related migraine referred to headache centres. Cephalalgia 2004;24(9):707-16
   PubMed Web of Science ®Google Scholar
• Hu Y, Guan X, Fan L, Jin L. Triptans in prevention of menstrual migraine: a systematic review with meta-analysis. J Headache Pain 2013;14(1):7
   PubMedGoogle Scholar
• Allais G, Castagnoli Gabellari I, De Lorenzo C, et al. Menstrual migraine: clinical and therapeutical aspects. Expert Rev Neurother 2007;7(9):1105-20
   PubMedGoogle Scholar
• Mannix LK, Martin VT, Cady RK, et al. Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials. Obstet Gynecol 2009;114(1):106-13
   PubMed Web of Science ®Google Scholar
• Allais G, Rolando S, Schiapparelli P, et al. Frovatriptan plus dexketoprofen in the treatment of menstrually related migraine: an open study. Neurol Sci 2013;34(Suppl 1):S179-81
   Web of Science ®Google Scholar
• Law S, Derry S, Moore RA. Sumatriptan plus naproxen for acute migraine attacks in adults. Cochrane Database Syst Rev 2013;10:CD008541
   PubMedGoogle Scholar
• Yang LP. Sumatriptan/naproxen sodium: a review of its use in adult patients with migraine. Drugs 2013;73(12):1339-55
   PubMedGoogle Scholar
• Krymchantowski AV, Barbosa JS. Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: an open label pilot study. Cephalalgia 2002;22(4):309-12
   PubMed Web of Science ®Google Scholar
• Krymchantowski AV, Bigal ME. Rizatriptan versus rizatriptan plus rofecoxib versus rizatriptan plus tolfenamic acid in the acute treatment of migraine. BMC Neurol 2004;4:10
   PubMed Web of Science ®Google Scholar
• Schoenen J, De Klippel N, Giurgea S, et al. Belgian Headache Society. Almotriptan and its combination with aceclofenac for migraine attacks: a study of efficacy and the influence of auto-evaluated brush allodynia. Cephalalgia 2008;28(10):1095-105
   PubMedGoogle Scholar
• McGettigan P, Henry D. Use of non-steroidal anti-inflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle-, and high-income countries. PLoS Med 2013;10(2):e1001388
   PubMed Web of Science ®Google Scholar